Trial Profile
Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Cardiovascular disorders; Dilated cardiomyopathy; Heart failure
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms CATHETER-DCM
- Sponsors Aastrom Biosciences
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Jan 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 according to ClinicalTrial.gov record..
- 03 Jan 2013 New trial record